Clinical Trials

A Phase II Study of Trebananib (AMG 386) for the Treatment of Inoperable Advanced Angiosarcoma

Protocol
12-128
Full Title
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma (Alliance A091103)
Purpose

Angiosarcoma is a rare type of soft-tissue sarcoma. The purpose of this study is to evaluate the safety and effectiveness of an investigational drug called trebananib in patients with advanced angiosarcoma that persists despite prior treatment and cannot be surgically removed.

Trebananib (also called AMG 386) works by inhibiting the development of the blood vessels that tumors need to grow and spread. It is given intravenously (by vein).

Investigator
Sandra P. D'Angelo, MD
Sandra P. D'Angelo - Physician Profile
Co-Investigators
William D. Tap, MD -- Section Chief, Sarcoma Oncology, Melanoma and Sarcoma Service
William D. Tap - Physician Profile
Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have advanced inoperable angiosarcoma.
  • Patients may have had up to four prior regimens of chemotherapy.
  • At least 4 weeks must have passed since completion of previous therapy and entry into the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • Patients must be age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Sandra D’Angelo at 646-888-4159.

Disease(s)
Sarcomas
Sarcomas: Soft Tissue Sarcoma
Locations
Related Diseases